| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Avidity Biosciences, Inc. (RNA) has 13 insiders with recent SEC Form 4 filings, including 1 buy and 15 sells. RNA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 283.4K | $3.67M | - | |
| Other | 205.0K | $2.65M | - | |
| Other | 116.9K | $1.51M | - | |
| Other | 91.6K | $1.19M | - | |
| Other | 79.0K | $1.02M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2023 | Levin Arthur A | Chief Scientific Officer | Sale+OE | 10,000 | $22.00 | $220,028.00 | -88.3% | |
| Dec 29, 2022 | Levin Arthur A | Chief Scientific Officer | Sale+OE | 40,000 | $22.01 | $880,568.00 | -96.8% | |
| Aug 25, 2022 | Boyce Sarah | President And CEO | Sale+OE | 49,900 | $22.88 | $1,141,614.36 | -100% | |
| Aug 16, 2022 | Levin Arthur A | Chief Scientific Officer | Sale+OE | 80,000 | $22.10 | $1,767,666.48 | -95.2% | |
| Aug 15, 2022 | Boyce Sarah | President And CEO | Sale+OE | 100 | $22.47 | $2,247.00 | -100% | |
| Nov 18, 2021 | Levin Arthur A | Chief Scientific Officer | Sale+OE | 25,000 | $27.89 | $697,217.50 | -94.9% | |
| Aug 4, 2021 | Rtw Investments, LP63 | 10% Owner | Buy | 800,000 | $18.00 | $14,400,000.00 | +20.0% | |
| Jun 25, 2021 | Levin Arthur A | Chief Scientific Officer | Sale+OE | 20,200 | $28.12 | $568,074.20 | -75.3% | |
| Jun 17, 2021 | Levin Arthur A | Chief Scientific Officer | Sale+OE | 200 | $27.75 | $5,550.00 | -13.1% | |
| Jun 15, 2021 | Levin Arthur A | Chief Scientific Officer | Sell | 37,022 | $25.98 | $961,988.53 | -61.7% |